5-aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer

Gut

Volumn 61, Issue 12, 2012, Pages 1708-1715

  Baan, Bart ^a,b   Dihal, Ashwin A ^b   Hoff, Eva ^b   Bos, Carina L ^c   Voorneveld, Philip W ^b   Koelink, Pim J ^b   Wildenberg, Manon E ^a   Muncan, Vanesa ^a   Heijmans, Jarom ^a   Verspaget, Hein W ^b   Richel, Dick J ^d   Hardwick, James C H ^b   Hommes, Daniel W ^b   Peppelenbosch, Maikel P ^e   Van Den Brink, Gijs R ^a,b  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; MAMMALIAN TARGET OF RAPAMYCIN; MESALAZINE; PHOSPHOLIPASE D; PROTEIN S6; ROSIGLITAZONE; SMALL INTERFERING RNA;

ARTICLE; BEDTIME DOSAGE; CANCER CELL; CANCER CELL CULTURE; CANCER PATIENT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TREATMENT RESPONSE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; HUMANS; MESALAMINE; PHOSPHOLIPASE D; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84868677242     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301626     Document Type: Article

References (31)

1. Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008;14:265-74. (Pubitemid 351288050)
2. Reinacher-Schick A, Schoeneck A, Graeven U, et al. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis 2003;24:443-51. (Pubitemid 36432639)
3. Stolfi C, Fina D, Caruso R, et al. Cyclooxygenase-2-dependent and -independent inhibition of proliferation of colon cancer cells by 5-aminosalicylic acid. Biochem Pharmacol 2008;75:668-76.
4. Koelink PJ, Mieremet-Ooms MA, Corver WE, et al. 5-aminosalicylic acid interferes in the cell cycle of colorectal cancer cells and induces cell death modes. Inflamm Bowel Dis 2010;16:379-89.
5. Luciani MG, Campregher C, Fortune JM, et al. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007;132:221-35. (Pubitemid 46108738)
6. Monteleone G, Franchi L, Fina D, et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ 2006;13:202-11. (Pubitemid 43102204)
7. Bos CL, Diks SH, Hardwick JC, et al. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis 2006;27:2371-82. (Pubitemid 44884094)
8. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptorgamma. J Exp Med 2005; 201:1205-15. (Pubitemid 40629065)
9. Schwab M, Reynders V, Loitsch S, et al. PPARgamma is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis 2008;29:1407-14.
10. Bjornsti MA, Houghton PJ. The TOR pathway: a target for cancer therapy. Nat Rev Cancer 2004;4:335-48. (Pubitemid 38579480)
11. Ma XM, Blenis J. Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 2009;10:307-18.
12. Long X, Lin Y, Ortiz-Vega S, et al. Rheb binds and regulates the mTOR kinase. Curr Biol 2005;15:702-13. (Pubitemid 40599924)
13. Huang J, Manning BD. The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 2008;412:179-90. (Pubitemid 351758225)
14. Wang L, Harris TE, Roth RA, et al. PRAS40 regulates mTORC1 kinase activity by functioning as a direct inhibitor of substrate binding. J Biol Chem 2007;282:20036-44. (Pubitemid 47100127)
15. Fang Y, Vilella-Bach M, Bachmann R, et al. Phosphatidic acid-mediated mitogenic activation of mTOR signaling. Science 2001;294:1942-5. (Pubitemid 33101594)
16. Toschi A, Lee E, Xu L, et al. Regulation of mTORC1 and mTORC2 complex assembly by phosphatidic acid: competition with rapamycin. Mol Cell Biol 2009; 29:1411-20.
17. Bus PJ, Nagtegaal ID, Verspaget HW, et al. Mesalazine-induced apoptosis of colorectal cancer: on the verge of a new chemopreventive era? Aliment Pharmacol Ther 1999;13:1397-402. (Pubitemid 29516250)
18. Sekulic A, Hudson CC, Homme JL, et al. A direct linkage between the phosphoinositide 3-kinase-AKT signaling pathway and the mammalian target of rapamycin in mitogen-stimulated and transformed cells. Cancer Res 2000;60:3504-13. (Pubitemid 30482170)
19. Holz MK, Blenis J. Identification of S6 kinase 1 as a novel mammalian target of rapamycin (mTOR)-phosphorylating kinase. J Biol Chem 2005;280:26089-93. (Pubitemid 41022201)
20. Laplante M, Sabatini DM. mTOR signaling at a glance. J Cell Sci 2009;122:3589-94.
21. Staerk LL, Stokholm M, Bukhave K, et al. Disposition of 5-aminosalicylic acid by olsalazine and three mesalazine preparations in patients with ulcerative colitis: comparison of intraluminal colonic concentrations, serum values, and urinary excretion. Gut 1990;31:1271-6.
22. Frieri G, Pimpo MT, Palumbo GC, et al. Rectal and colonic mesalazine concentration in ulcerative colitis: oral vs. oral plus topical treatment. Aliment Pharmacol Ther 1999;13:1413-17. (Pubitemid 29516252)
23. Rhodes JM, Bartholomew TC, Jewell DP. Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 1981;22:642-7. (Pubitemid 11018267)
24. Fox CC, Moore WC, Lichtenstein LM. Modulation of mediator release from human intestinal mast cells by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1991;36:179-84.
25. Ha SH, Kim DH, Kim IS, et al. PLD2 forms a functional complex with mTOR/raptor to transduce mitogenic signals. Cell Signal 2006;18:2283-91. (Pubitemid 44636169)
26. Lehma n N, Ledford B, Di FM, et al. Phospholipase D2-derived phosphatidic acid binds to and activates ribosomal p70 S6 kinase independently of mTOR. FASEB J 2007;21:1075-87.
27. Zhao C, Du G, Skowronek K, et al. Phospholipase D2-generated phosphatidic acid couples EGFR stimulation to Ras activation by Sos. Nat Cell Biol 2007;9:706-12.
28. Tsukahara T, Tsukahara R, Fujiwara Y, et al. Phospholipase D2-dependent inhibition of the nuclear hormone receptor PPARgamma by cyclic phosphatidic acid. Mol Cell 2010;39:421-32.
29. Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008;(27 Suppl 2):S43-51.
30. Foster DA, Xu L. Phospholipase D in cell proliferation and cancer. Mol Cancer Res 2003;1:789-800. (Pubitemid 37174450)
31. Saito M, Iwadate M, Higashimoto M, et al. Expression of phospholipase D2 in human colorectal carcinoma. Oncol Rep 2007;18:1329-34.